Batoclimab (IMVT-1401): The FcRn Blocker That Worked in Phase 3 - and Was Deliberately Not Filed (July 26, 2026)
Table of Contents
- A fourth FcRn blocker - and the one that got away
- A full human antibody you inject yourself at home
- The Phase 3 that worked: myasthenia gravis
- Strong signals in CIDP and Graves' disease
- The honest part: it failed in thyroid eye disease - and it taxes albumin
- Why the drug that worked was shelved: enter IMVT-1402
- How it fits the FcRn class - and what to take away
A fourth FcRn blocker - and the one that got away
Over the last three days this series introduced the three FcRn blockers on the U.S. market - efgartigimod (Vyvgart), nipocalimab (Imaavy) and rozanolixizumab (Rystiggo). All three stop the neonatal Fc receptor, the recycling depot that normally rescues immunoglobulin G from destruction, so pathogenic autoantibodies get cleared and total IgG drops. Batoclimab (development codes IMVT-1401, RVT-1401, HBM9161, HL161) does exactly the same thing. But it is the class member you cannot get a prescription for, because the companies developing it chose not to file it - even after it worked. That decision, not the molecule, is what makes batoclimab worth a close look: it is the clearest case study in how a drug class upgrades itself from first generation to best-in-class.
A full human antibody you inject yourself at home
Batoclimab is a fully human, full-length IgG1 monoclonal antibody that binds FcRn at its IgG-binding site with high affinity - a complete antibody, unlike efgartigimod's engineered Fc fragment. It originated at South Korea's HanAll Biopharma as HL161 and is licensed to Immunovant/Roivant for the U.S. and Canada and to Harbour BioMed for Greater China. Its signature is delivery: a small, fixed-dose subcutaneous injection designed for at-home self-administration, contrasting with efgartigimod's cyclic infusions, nipocalimab's IV maintenance and rozanolixizumab's on-body infusion device. Mechanistically it is textbook FcRn blockade - occupy the receptor, and unrescued IgG including autoantibodies is degraded, lowering total IgG by roughly 65-80% while sparing IgM, IgA and complement.
The Phase 3 that worked: myasthenia gravis
In March 2025, Immunovant reported that a Phase 3 study of batoclimab in generalized myasthenia gravis met its primary endpoint. The 680 mg once-weekly dose delivered a 5.6-point improvement in MG-ADL at Week 12 in anti-AChR-antibody-positive patients, alongside roughly 74% mean IgG reduction - numbers fully competitive with the approved FcRn agents. In China, Harbour BioMed had already reported positive Phase 3 gMG results with the same molecule (HBM9161) and filed a Biologics License Application with the NMPA, accepted in June 2023 and resubmitted with long-term extension data in June 2024. By any normal reading, this was an approvable myasthenia drug.
Strong signals in CIDP and Graves' disease
The breadth was real. In a Phase 2b CIDP study reported the same day as the myasthenia data, batoclimab produced a mean adjusted INCAT improvement of 1.8 across arms and an 84% responder rate among patients who lowered IgG by more than 70%, with meaningful gains on I-RODS, MRC sum score and grip strength. In Graves' disease - a harder, autoantibody-driven hyperthyroidism - batoclimab posted some of the most striking data in the entire FcRn class: roughly 80% of responders kept normalized thyroid hormone at Week 48, and about half reached anti-thyroid-drug-free remission six months after stopping treatment. Durable, off-treatment remission is the holy grail in autoimmune disease, and batoclimab flashed it.
The honest part: it failed in thyroid eye disease - and it taxes albumin
Two things complicate the story. First, in April 2026 both Phase 3 GO trials of batoclimab in thyroid eye disease missed the primary endpoint of a 2 mm or greater reduction in proptosis at Week 24 - a direct echo of rozanolixizumab's negative CIDP result and a reminder that depleting IgG does not resolve every antibody-associated disease. Second, and more consequentially, batoclimab carries a distinctive on-target liability: because FcRn recycles serum albumin as well as IgG, deep sustained blockade reproducibly lowers serum albumin and raises LDL and total cholesterol. That lab signature is not a quirk - it is the mechanism showing its edges, and it is the exact problem the next molecule was built to solve.
Why the drug that worked was shelved: enter IMVT-1402
Here is the twist. Despite hitting its myasthenia endpoint and generating best-in-disease Graves' data, Immunovant/Roivant announced they would NOT seek U.S. approval for batoclimab in myasthenia gravis or CIDP. Instead, batoclimab became clinical proof-of-concept for a re-engineered successor, IMVT-1402 - an FcRn antibody designed to deliver the same deep IgG lowering without the albumin drop and lipid rise. IMVT-1402 is now the strategic priority across multiple autoimmune diseases, with Graves' disease as a flagship indication and potentially registrational readouts expected in 2027. Batoclimab, in other words, was used to de-risk a target and then deliberately handed the market to its own improved version - a rare, transparent look at portfolio strategy in action.
How it fits the FcRn class - and what to take away
Placed beside its peers, batoclimab completes the picture: efgartigimod (Fc fragment, cyclic), nipocalimab (aglycosylated IgG1, IV maintenance), rozanolixizumab (IgG4, subcutaneous cycles) and batoclimab (fully human IgG1, self-injected) - the same target reached four different ways. Its identifiers are DrugBank DB16104 and CAS 2187430-05-1. The practical takeaway for anyone tracking peptide and antibody therapeutics: a positive Phase 3 does not guarantee a launch, an on-target lab change can decide a molecule's fate, and the FcRn story is still being written - most of its future now rides on the albumin-sparing IMVT-1402. And a standing caution: batoclimab is investigational and prescription-only in trials, so any 'batoclimab' or 'IMVT-1401' sold by a research-chemical vendor is unverified and should not be used.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and CIDP Studies - Immunovant, March 2025 Source
- [2] Immunovant Reports Positive Phase 3 and Phase 2b Results for Batoclimab in MG and CIDP - NeurologyLive, March 2025 Source
- [3] Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) - Immunovant, April 2026 Source
- [4] Immunovant Unveils Durability and Treatment-Free Six-month Remission Data in Uncontrolled Graves' Disease - Immunovant Source
- [5] Harbour BioMed Announces BLA Acceptance of Batoclimab (HBM9161) for Generalized Myasthenia Gravis by NMPA Source
- [6] Batoclimab: Uses, Interactions, Mechanism of Action - DrugBank DB16104 Source
Related Articles
Efgartigimod (Vyvgart): The Antibody Fragment That Treats Autoimmune Disease by Deleting Your Own Antibodies (July 23, 2026)
Most autoimmune drugs suppress the whole immune system. Efgartigimod does something narrower and stranger: it blocks the receptor that recycles your antibodies, so your own pathogenic IgG gets thrown out with the trash. In May 2026 the FDA made it the first and only myasthenia gravis drug approved for every antibody serotype.
Nipocalimab (Imaavy): The FcRn Blocker That Went Everywhere - From Myasthenia Gravis to the Womb (July 24, 2026)
A day after efgartigimod, meet the other FcRn blocker. Nipocalimab uses the same trick - stop the receptor that recycles your antibodies - but as a full antibody, dosed continuously, and pushed into places no rival has gone: rheumatology, hematology, and even pregnancy.
Rozanolixizumab (Rystiggo): The Subcutaneous FcRn Blocker That Reached Both Myasthenia Serotypes First (July 25, 2026)
Two days after efgartigimod and one after nipocalimab, meet the third FcRn blocker. Rozanolixizumab uses the same trick - stop the receptor that recycles your antibodies - but delivered under the skin, in cycles, and it was the first drug approved to cover both the AChR- and MuSK-antibody myasthenia serotypes. It's also an honest lesson in the mechanism's limits: it failed in CIDP.
IMVT-1402 (Imeroprubart): The Albumin-Sparing FcRn Blocker Built to Replace Batoclimab (July 27, 2026)
Yesterday we told the story of batoclimab - the FcRn blocker that worked in Phase 3 and was deliberately shelved. Today, meet its replacement. IMVT-1402 (imeroprubart) was engineered to lower IgG just as deeply as batoclimab while sparing the serum albumin and LDL cholesterol that sank its predecessor. It is now Immunovant's lead asset, with registrational Graves' and myasthenia readouts due in 2027.